The investigators hypothesise that H2H will result in improved symptom control and quality of
life and may be more cost-effective than standard best practice.
Interstitial Lung Disease (ILD) is a lung condition characterised by progressive scarring -
known as fibrosis. This is especially seen in patients with idiopathic pulmonary fibrosis
(IPF). There around 2,000 new patients diagnosed in the UK every year with a similar number
Fibrotic-ILD causes breathing to slowly deteriorate and as there is no cure, an estimated
two-thirds of patients die within five years of diagnosis. Patients suffer from many symptoms
including shortness of breath, cough, low mood and fatigue which are currently being poorly
managed. In addition, these patients suffer a poor health related quality of life whilst
dying from their disease.
In the later stages of their disease, these patients often end up in hospital (see appendix
1a) when there is no proven or effective treatment. Many die there despite wishing to be
looked after and die at home. These patients rarely receive palliative care which may help to
improve their symptoms, quality of life, address end of life planning needs and prevent
hospital admission. The Hospital2Home case conference conducted in the patient's home (or
place of their choice) aims to address this. At the case conference involving the patient,
their carers, a specialist nurse, and all the community health professionals, a care plan
specific to the patient will be developed. Each health professional will be aware of their
responsibility and duties. The investigators will look at whether this results in better
symptom control and better quality of life for the patient and their carer. The investigators
will also examine whether this prevents emergency hospital admission and allows patients to
die in their preferred place. The investigators will compare patients who receive the service
immediately with those who receive it after a delay.